Federal cuts to Medicaid and food aid threaten to worsen health, hunger, and housing challenges for low-income seniors in ...

NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers ...